KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Cash & Equivalents (2016 - 2025)

Charles River Laboratories International has reported Cash & Equivalents over the past 17 years, most recently at $213.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 9.85% year-over-year to $213.8 million; the TTM value through Dec 2025 reached $213.8 million, up 9.85%, while the annual FY2025 figure was $213.8 million, 9.85% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $213.8 million at Charles River Laboratories International, up from $207.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $465.4 million in Q1 2021 and troughed at $157.2 million in Q3 2023.
  • A 5-year average of $229.6 million and a median of $211.4 million in 2021 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: plummeted 48.03% in 2022 and later skyrocketed 62.23% in 2024.
  • Year by year, Cash & Equivalents stood at $241.2 million in 2021, then dropped by 3.03% to $233.9 million in 2022, then rose by 18.32% to $276.8 million in 2023, then decreased by 29.69% to $194.6 million in 2024, then rose by 9.85% to $213.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for CRL at $213.8 million in Q4 2025, $207.1 million in Q3 2025, and $182.8 million in Q2 2025.